Mark Justin D, Colombo Rosario A, Alfonso Carlos E, Llanos Alexander, Collado Elias, Larned Joshua M, Giese German, Dyal Michael D, Nanna Michael G, Damluji Abdulla A
Department of Internal Medicine, University of Miami Miller School of Medicine, Holy Cross Health, Fort Lauderdale, Florida, USA.
Division of Cardiology, University of Miami Miller School of Medicine, Jackson Memorial Hospital, Miami, Florida, USA.
JACC Adv. 2024 Nov 7;3(11):101358. doi: 10.1016/j.jacadv.2024.101358. eCollection 2024 Nov.
Frailty is a common geriatric syndrome often coexisting with cardiovascular diseases such as atrial fibrillation (AF) and heart failure (HF) with reduced ejection fraction (HFrEF). While catheter ablation (CA) has demonstrated efficacy in reducing major adverse cardiovascular events and improving mortality and quality of life, the influence of frailty among this population remains unknown.
The authors aimed to identify the prevalence of frailty among patients with HFrEF and AF undergoing CA and its influence on cardiovascular mortality and discharge disposition.
From January 2016 to December 2019, we used the Nationwide Inpatient Sample to identify patients with AF and HFrEF. Frailty was identified by the presence of ≥1 diagnostic cluster utilizing the Johns Hopkins Adjusted Clinical Groups with malnutrition, dementia, impaired vision, decubitus ulcer, urinary incontinence, loss of weight, poverty, barriers to access to care, difficulty walking, and falls as indicators. We compared clinical outcomes among frail vs nonfrail patients, including all-cause in-hospital mortality, major adverse cardiovascular events, other major complications, discharge disposition, and hospital length of stay using multivariable regression analysis.
Of 113,115 weighted admissions, 11,725 (10.4%) were classified as frail. Frail patients were older (median age: 76 [IQR: 15] years vs 70 [IQR: 15] years, < 0.001) than nonfrail patients. Frailty was associated with increased odds of all-cause hospital mortality (adjusted odds ratio [aOR]: 2.64; 95% CI: 1.87-3.72; < 0.001), major adverse cardiovascular events (aOR: 2.00; 95% CI: 1.62-2.47; < 0.001), and nonhome discharge (aOR: 3.31; 95% CI: 2.78-3.94; < 0.001). Frail patients also experienced longer hospital length of stay (median 9 [IQR: 10] days vs 5 [IQR: 5] days, < 0.001) after adjustment by Poisson regression (coefficient: 0.53; 95% CI: 0.46-0.59; < 0.001).
Frailty is associated with worse outcomes in patients with HFrEF undergoing CA for AF. The integration of frailty models in clinical practice may facilitate prognostication and risk stratification to optimize patient selection for CA.
衰弱是一种常见的老年综合征,常与心血管疾病并存,如心房颤动(AF)和射血分数降低的心力衰竭(HFrEF)。虽然导管消融(CA)已证明在减少主要不良心血管事件、改善死亡率和生活质量方面有效,但衰弱对这一人群的影响仍不清楚。
作者旨在确定接受CA治疗的HFrEF和AF患者中衰弱的患病率及其对心血管死亡率和出院处置的影响。
2016年1月至2019年12月,我们使用全国住院患者样本确定AF和HFrEF患者。利用约翰霍普金斯调整临床分组,以营养不良、痴呆、视力受损、褥疮、尿失禁、体重减轻、贫困、就医障碍、行走困难和跌倒为指标,通过存在≥1个诊断聚类来确定衰弱。我们使用多变量回归分析比较了衰弱与非衰弱患者的临床结局,包括全因住院死亡率、主要不良心血管事件、其他主要并发症、出院处置和住院时间。
在113115例加权入院患者中,11725例(10.4%)被归类为衰弱。衰弱患者比非衰弱患者年龄更大(中位年龄:76[四分位间距:15]岁对70[四分位间距:15]岁,<0.001)。衰弱与全因住院死亡率增加(调整优势比[aOR]:2.64;95%置信区间:1.87-3.72;<0.001)、主要不良心血管事件(aOR:2.00;95%置信区间:1.62-2.47;<0.001)和非家庭出院(aOR:3.31;95%置信区间:2.78-3.94;<0.